FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 319:70-75 July 14, 1988 Number 2 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Cobalamin deficiency has well-known hematologic and neurologic effects, but little is known about its other effects. We therefore studied the effect of cobalamin on osteoblast-related proteins. We found that mean (+/- 1 SD) levels of skeletal alkaline phosphatase in the blood were lower in 12 cobalamin-deficient patients (3.89 +/- 2.19 units per liter) than in 5 nondeficient and 5 iron-deficient control subjects (7.55 +/- 3.99 units per liter). The degree of the megaloblastic anemia correlated with the reduction in skeletal alkaline phosphatase levels (r = 0.67, P less than 0.01). With cobalamin therapy, levels of skeletal alkaline phosphatase rose in 11 of the 12 cobalamin-deficient subjects but not in the controls. The cobalamin-deficient patients also had significantly lower osteocalcin levels than the control subjects (1.11 +/- 0.77 vs. 1.84 +/- 0.49 nmol per liter). During cobalamin therapy, these levels rose in the cobalamin-deficient patients but not in the controls. In contrast to the levels of osteoblast-related proteins, hepatic alkaline phosphatase levels were similar in the patients and controls and were usually unaffected by cobalamin therapy. In vitro studies of calvarial cells from chicken embryos showed that their alkaline phosphatase content was cobalamin-dependent, thus supporting our in vivo observations in humans. Our findings suggest that osteoblast activity depends on cobalamin and that bone metabolism is affected by cobalamin deficiency, but we do not yet know whether cobalamin deficiency produces clinically important bone disease.

Source Information

Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.

This article has been cited by other articles:

• Herrmann, M., Widmann, T., Colaianni, G., Colucci, S., Zallone, A., Herrmann, W. (2005). Increased Osteoclast Activity in the Presence of Increased Homocysteine Concentrations. Clin. Chem. 51: 2348-2353 [Abstract] [Full Text]  
• Sugiyama, T., Tanaka, H., Taguchi, T. (2005). Folate and Vitamin B12 for Hip Fracture Prevention After Stroke. JAMA 294: 792-792 [Full Text]  
• van Meurs, J. B. J., Uitterlinden, A. G. (2005). Homocysteine and Fracture Prevention. JAMA 293: 1121-1122 [Full Text]  
• Stone, K. L., Bauer, D. C., Sellmeyer, D., Cummings, S. R. (2004). Low Serum Vitamin B-12 Levels Are Associated with Increased Hip Bone Loss in Older Women: A Prospective Study. J. Clin. Endocrinol. Metab. 89: 1217-1221 [Abstract] [Full Text]  
• Dhonukshe-Rutten, R. A. M., Lips, M., de Jong, N., Chin A Paw, M. J. M., Hiddink, G. J., van Dusseldorp, M., de Groot, L. C. P. G. M., van Staveren, W. A. (2003). Vitamin B-12 Status Is Associated with Bone Mineral Content and Bone Mineral Density in Frail Elderly Women but Not in Men. J. Nutr. 133: 801-807 [Abstract] [Full Text]  
• Carpenter, C. L., Patalas, E. D. (2000). Case 40-2000- A 38-Year-Old Woman with Gastric Adenocarcinoma. NEJM 343: 1951-1958 [Full Text]